Purpose or Objective:
The use of postoperative radiotherapy (RT) in patients (pts) at risk for local recurrence is well established for many tumours. The postoperative subgroup of the AIRO Working Group on Prostate RT carried out a multiinstitutional prospective study to evaluate the impact of Adjuvant RT (PORT) and Salvage RT (SART) on biochemical outcomes in prostate cancer pts.
Material and Methods:
Between January 2002 and December 2003, data of 440 pts (mean age: 65 years, range 42-81) treated with radical prostatectomy (RP) were collected by 14 Italian RT Departments. Of the 411 pts available for the 10 year analysis (median follow up: 111 months), 284 (69.1%) received PORT (started <6 months after RP) and 127 underwent SART because of increasing PSA level after having been undetectable or persistently elevated PSA (> 6 months after RP). Gleason Score (GS) > 7 and positive surgical margins (SM+) have been shown by 69% pts and 74.5% respectively; 76.5% presented locally advanced disease (pT3-4), 27 (6.7%) positive pelvic nodes; 163 pts (40.2%) revealed seminal vesicles invasion (SVI). All pts received RT to the prostatic fossa (mean dose of 67.8 Gy, range: 60-76). Pelvic RT was delivered to 111 pts (27%). Androgen deprivation (AD) was prescribed to 47,3% pts. Among 127 SART pts, pre-RT PSA level was 1 ng/mL or less in 56 pts (44,1%).
Results: Ten year analysis shows that 259 pts are disease free and 331 are still alive. 10 year (10-y) overall survival and biochemical control (BC) rate are 75.9% and 57.8% respectively. On univariate analysis, PORT versus SART, SVI and GS > 7 significantly influenced 10-y BC rate: 62.7% in PORT group versus 45.6% SART one (p = 0.003), 56.9% in pts with SVI versus 65.6% pts without SVI (p < 0.001), 52.5% if GS > 7 and 69.8% if GS < 7 (p= 0.003). SM+, pathological T and N stages, AD or pelvic RT had no impact on biochemical recurrence rate. SVI and PORT versus SART were variables associated with BC on multivariate analysis. Only pre-RT PSA level significantly influenced disease free survival in SART setting: when the pre-RT PSA was 1 ng/mL or less, 59.8% pts were disease free at 10-y compared with 33.5% of those treated at PSA levels greater than 1 ng/mL (p= 0.017).
Conclusion:
Pts in PORT group, pts without SVI and with GS < 7 show better BC rates . Postoperative RT delivered in high risk prostate cancer patients can reduce the impact of other common unfavourable prognostic factors (pT stage, positive surgical margins). Early referral for SART offers better disease control after radical prostatectomy. This prospective multicenter study confirms outcomes of other series. Purpose or Objective: A bladder-preserving strategy, combining transurethral resection of the bladder tumor (TUR-B) with radiochemotherapy, results in a long-term overall survival comparable to cystectomy. However, such a strategy is mostly applied to elderly or unfit patients, but their medical status regularly contraindicates chemotherapy. This leaves the combination of TUR-B and radical radiotherapy as the only treatment option. For this vulnerable patient group, reduction of toxicity is of additional importance, which could be obtained by more conformal treatment plans. It was our aim to retrospectively analyze the treatment outcome and associated toxicity of both conformal and intensitymodulated radiotherapy (IMRT) using a tumor boost, for locally advanced bladder cancer in patients not suitable for cystectomy.
Material and Methods:
119 patients with T1-4 N0-1 M0 bladder cancer were analyzed retrospectively. Median age was 80 years. Patient and treatment characteristics can be found in Table 1 . Treatment consisted of either a conformal box technique or IMRT. Patients were treated with 40 Gy in 20 fractions to the elective treatment volumes, and a daily boost of 0.75 Gy to the tumor. This resulted in a tumor boost of either 55 Gy or 60 Gy, the latter in case expected toxicity allowed delivery of two additional 2.5 Gy fractions to the tumor. Cystoscopic placement of fiducial markers aided in tumor delineation. To evaluate response, a cystoscopy was performed two months after treatment and thereafter every six months. To assess toxicity, patients were seen by their oncologist every week during the treatment course, and thereafter with 1-12 month intervals until up to 5 years after treatment. Toxicity was scored according to the CTCAE version 4, with acute toxicity defined as occurring during treatment or within the first three months thereafter. The Kaplan-Meier method was used to estimate survival and locoregional control. Possible predictors for survival were examined in univariate Cox proportional hazard regression analyses. Differences in toxicity between IMRT or conformal radiotherapy were tested using χ2 tests.
Results:
At 3 months, a complete response was seen in 87% of patients. 3-year overall survival was 44%, with a locoregional control rate of 72% at three years ( Figure 1) . Including pelvic lymph nodes in the elective field increased survival significantly (hazard ratio: 0.58, p = 0.04). Late toxicity was low, with urinary and intestinal toxicity grades ≥ 2 of 14% and 5%, respectively. IMRT reduced late intestinal toxicity grade ≥ 1 from 24% to 7% (p=0.04), as well as acute intestinal toxicity grade ≥ 2 (from 36% to 12%, p = 0.03).
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Conclusion: Radical radiotherapy is feasible and effective for elderly or unfit patients. Three-year locoregional control after radical radiotherapy using a boost technique was 72%, with low rates for late urinary and intestinal toxicity. Early and late toxicity rates were reduced by using IMRT. 
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Purpose or Objective: We conducted a phase I trial of Gemcitabine (GEM) with concomitant 3D-Conformal Radiotherapy (3D-CRT) and Cisplatin (CDDP) in patients with muscle-invasive bladder cancer who were ineligible for surgery or refused organ loss.
Material and Methods:
28 patients with transitional cell carcinoma, cT2(n = 14), cT3(n = 8), T4a(n = 6), cN0-1, M0, median age 70.5 years were included after maximal transurethral resection. 3D-CRT was administered with a 18MV Linac, 1.8Gy/Fr, 5d/week up to 64.80Gy. The GEM starting dose of 40mg/m2/week was increased by 40mg/m2 increments to 2 levels (80 and 120mg/m2/week) in cohorts of 6 patients. The standard dose of CDDP was 25mg/m2/week given 2 days after GEM infusion. Both drugs were given 30 to 60min before irradiation Results: All patients were evaluated for toxicity which was evaluated according to the Common Toxicity Criteria and the RTOG/EORTC Score. The DLTs (Dose Limiring Toxicities) were defined as hematologic grade >3 or Non-hematologic grade 3 events, as Abdominal pain/Diarrhea (Proctitis), Dysuria/Urinary frequency (Cystitis), Fatigue/Asthenia, not resolving tro grade 1/2 within 2 days or necessitating the interruption of RT for >1 week, in more than 3 of 6 patients in each cohort. The GEM dose immediately before the level at which the DLT was observed was defined as the Maximum Tolerated Dose (MTD). In 6 patients accrued to GEM dose 40mg/m2/week no grade 3 toxicities were seen. From 6 patients given 80mg/m2/week of GEM, 2 had episodes of grade 3 bladder toxicity, 3 General Weakness and 2 presented with grade 3 hematological sequelae. From 6 patients accrued to GEM dose 120mg/m2/week, 4 had episodes of grade 3 neutropenia and/or thrombocytopenia and 3 showed grade 3 fatigue/malaise. In 4 patients treatment was interrupted for more than 1 week. The 2-year locoregional failure rate was 28% (8/28). 12 of 28 (42%) patients are alive with no evidence of disease progression, 8 patients developed M1 disease and 5 died from this.
Conclusion: GEM given synchronously with 3D-CRT is well tolerated as a bladder preservation schema. The MTD was defined at 80mg/m2/week combined to CDDP and merits evaluation in phase II/III trials. Purpose or Objective: Wide surgical excision is the standard treatment for angiosarcoma of the scalp, but it is often difficult to completely excise because of the invasive nature and typical multifocal spread of the tumor. Furthermore, many patients are medically inoperable because of old age or coexisting disease. Therefore, we investigated the outcome of radiation therapy with total scalp irradiation for angiosarcoma of the scalp.
Seventeen patients with angiosarcoma of the scalp underwent radiation therapy with total scalp irradiation with curative intent. Their median age at the time of irradiation was 77 (range, 57-89) years. Four of the 17 patients had tumor invasion into the deep organs, including the skull in three and the temporal muscle in one. Four patients had cervical lymph node metastases, but none had distant metastases. A median initial dose of 50 Gy in 25 fractions was delivered to the entire scalp. Two pairs of lateral X-ray and electron fields were used for total scalp irradiation: 4-6 MV X-rays were delivered through bilaterally opposed ports to the central scalp from the frontal eminence to the suboccipital region, to a depth of 10 mm inside the skull, and 5-9 MeV electrons were delivered through single ports to the bilateral temporal scalp. Subsequently, local radiation boost to the tumor sites achieved a median total dose of 70 Gy in 35 fractions. Results: All irradiated tumors disappeared or were markedly reduced after radiation therapy; the objective response rate was 100%. However, 14 of the 17 patients developed recurrences during the median follow-up period of 14 months after radiation therapy; seven had recurrences in the scalp, including primary tumor progression in two patients and new disease in five, and 12 patients developed distant metastases. The two patients with primary tumor progression originally had tumor invasion into the skull and temporal muscle, and received a total radiation dose of 70 Gy in 35 fractions. The primary progression-free, scalp relapse-free,
